Skip to content
Study details
Enrolling now

A Study of LY3867070 in Healthy Participants

Eli Lilly and Company
NCT IDNCT07021547ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

196

Study length

about 1.3 years

Ages

18–65

Locations

2 sites in CA, TX

What this study is about

This trial is testing a new medication called LY3867070 in healthy people. The goal is to see if the medication is safe and what side effects might occur. Blood tests will be done to understand how the body processes the medication.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take LY3867070
  • 2.Take Placebo

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Number of Participants with One or More Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration, Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration, Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) Considered by the Investigator to be Related to Study Drug Administration

Secondary: PK: Maximum Concentration (Cmax) of LY3867070, Part B Pharmacodynamic (PD): Change from Baseline in Gene Expression, Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3867070